PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

NCT ID: NCT04787302

Last Updated: 2023-07-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2023-07-14

Brief Summary

PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing

Detailed Description

CVL-231 is a muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype (M4 mAChR). CVL-231 is being developed for treatment of psychosis in schizophrenia. The aim of this trial is to characterize the relationship between the M4 receptor occupancy in different regions of the brain following a single oral doses of CVL-231 in healthy adult subjects by positron emission tomography (PET) using the radioligand [11C]MK-6884.

Conditions

Schizophrenia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

CVL-231

Group Type: EXPERIMENTAL

CVL-231

Intervention Type: DRUG

Cohort 1: 30mg dose of CVL-231

CVL-231

Intervention Type: DRUG

Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded

CVL-231

Intervention Type: DRUG

Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2

Interventions

CVL-231

Cohort 1: 30mg dose of CVL-231

Intervention Type: DRUG

CVL-231

Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded

Intervention Type: DRUG

CVL-231

Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2

Intervention Type: DRUG

Other Intervention Names

PF-06852231; PF-06852231; PF-06852231

Eligibility Criteria

Inclusion Criteria

• Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 55 years, inclusive, at the time of signing the ICF
• Sexually active men with a pregnant or a nonpregnant partner of childbearing potential must agree to use a double-barrier method of birth control, including a condom, and practice contraception during treatment and through 7 days post dose
• Capable of providing informed consent and following study requirements

Exclusion Criteria

• Subjects who answer yes on the C-SSRS or, in the opinion of the investigator, present a serious risk of suicide
• Subjects with a current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or neurological disease
• Subjects with a 12-lead ECG demonstrating either of the following (average of 3 ECGs obtained at the Screening Visit):

• QT interval corrected for heart rate using Fridericia's formula >450 msec
• Left ventricular hypertrophy
• Orthostatic hypotension, which is defined as a decrease of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in diastolic blood pressure after at least 3 minutes of standing compared with the immediately previous supine/semi-recumbent blood pressure at Screening or at the prescan time point prior to baseline PET scan.
• Subjects with a current or past personal history of any psychiatric disorder as classified by DSM-5 criteria or immediate family members with any psychiatric disorder as classified by DSM-5 criteria that require treatment
• Subjects with a history of substance or alcohol-use disorder (DSM-5 criteria) within 2 years prior to signing the ICF
• Subjects with other abnormal laboratory test results, vital sign results, or ECG findings
• Subjects who currently use or have used tobacco or nicotine-containing products within 30 days prior to signing the ICF
• Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure (5 rem per year)
• Subjects with any anatomical abnormality in the head that would either preclude or tend to confound the analysis of study data, including any clinically significant abnormal findings from MRI of the head
• Current, past or anticipated exposure to radiation in the workplace
• Any subject with a significant acute illness within 7 days prior to administration of study drug or have had a major illness or hospitalization within 1 month prior to administration of study drug
• Any subject who, in the opinion of the sponsor, investigator, or medical monitor, should not participate in the trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cerevel Therapeutics, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Matthew Leoni, MD, MBA

Role: STUDY_DIRECTOR

Cerevel Therapeutics, LLC

Locations

Massachusetts General Hospital Translational and Clinical Research Centers

Boston, Massachusetts, United States

UZ Leuven

Leuven, , Belgium

Countries

United States; Belgium

Other Identifiers

CVL-231-1002

Identifier Type: -

Identifier Source: org_study_id